Rescheduling Delay: Why the DEA Pause Isn't the End

October 12, 2026

Photo by succo via Pixabay.

Marijuana rescheduling isn't dead. It's on pause, and there's a real deadline attached to that pause sitting on the calendar right now. On September 29, DEA Chief Administrative Law Judge Derek C. Julius issued an order halting the rulemaking proceeding that was supposed to produce his recommendation to DEA Administrator Terry Cole on whether cannabis should move from Schedule I to Schedule III. The government and any other interested parties have until October 13 to respond to the motion that triggered the stay. That's today or tomorrow, depending on when you're reading this.

It's worth stepping back to see how long this has already taken. The Biden administration recommended Schedule III back in August 2023. Hearings were supposed to start in January 2025. They didn't. When testimony finally began, it dragged into 2026, wrapping on July 15 of that year, with post-hearing briefs filed a month later. So after three years, dozens of stakeholders, and thousands of pages of transcripts, the entire proceeding is now held up by something that has nothing to do with whether cannabis has medical value or abuse potential — it's a Government Accountability Office report about internal paperwork gaps at DEA and FDA. That's the tension worth understanding: a nonbinding recommendation, already years overdue, now waiting on a fight over whether a federal audit of agency documentation practices needs to be read first.

What the September 29 Stay Actually Did

Photo by QuinceCreative via Pixabay.

The September 29 order didn't kill rescheduling or even signal skepticism about it. Judge Julius simply paused the rulemaking proceeding, which delays the point at which he issues his recommended decision to Administrator Cole. That recommendation is advisory — Cole isn't bound by it — but it's still the procedural linchpin everyone has been waiting on since the hearing record closed.

The stay exists because of a motion filed one day earlier, on September 28, by three parties who've been active participants in the proceeding: DUID Victim Voices, physician Kenneth Finn, and the National Drug & Alcohol Screening Association. These groups have consistently pushed back against Schedule III, and their motion asked Julius to admit a newly published GAO report into the record and allow briefing on it before he rules, rather than issuing a recommendation that ignores a federal watchdog document that landed squarely on DEA and FDA's scheduling process.

Julius agreed to pause rather than deny the motion outright, which means the government now has to respond by October 13, and other interested parties in the proceeding get the same deadline to weigh in. That response will likely shape whether the GAO report gets folded into the record for real, triggering additional briefing, or gets dismissed as irrelevant to the specific marijuana scheduling question at hand.

None of this reverses the underlying move toward Schedule III. It's a scheduling dispute over scheduling of filings, not a verdict. But procedural pauses in a process this politically watched have a way of adding months rather than weeks, and that's the practical cost here regardless of how the legal argument ultimately shakes out.

How the Process Got Here: A Three-Year Slog

Photo by retzer_c via Pixabay.

To understand why a few weeks of delay matters, you have to look at the full arc. A Schedule III recommendation was sent to DEA in August 2023, based on a scientific and medical evaluation requested by President Biden a year earlier. DEA accepted the recommendation for formal rulemaking review, and an administrative hearing was scheduled for January 2025 — a hearing that, for reasons tied to procedural challenges over who qualified as a legitimate party, never actually convened on that date.

The hearing eventually did happen, running into 2026 and finally concluding on July 15. Parties then filed post-hearing briefs on August 17, and Judge Julius released more than 2,500 pages of hearing transcripts on August 25 — a dense public record covering testimony from medical experts, addiction specialists, industry representatives, and advocacy groups on both sides.

At that point, with briefing complete and the transcript public, a lot of close observers figured a recommended decision could land before the 2026 midterms, giving the issue one more moment of political relevance before voters went to the polls. The September 29 stay scrambles that timeline. Whether it delays things by a month or well into next year depends largely on how Julius rules after the October 13 responses come in, and whether the losing side on that procedural question tries to escalate it further. Three years in, the pattern has been consistent: every time this process looks close to a milestone, something pushes the milestone back.

The GAO Report Behind the Delay

Of the 95 DEA scheduling decisions requiring HHS input reviewed by GAO between 2020 and 2025, DEA followed HHS's recommendation in 84 cases, while 11 remain unfinalized.

The report at the center of this is GAO-26-107 — officially titled Drug Scheduling: While DEA Decisions Have Aligned with Recent HHS Recommendations, Both Need Comprehensive Policies — published September 23, 2026. It's a broad look at how DEA handles scheduling decisions generally, not a document written about marijuana specifically, which is part of what makes its sudden relevance to this proceeding notable.

GAO reviewed 208 substances that went through DEA scheduling actions between 2020 and 2025. Of those, 95 required DEA to weigh a scientific or medical recommendation from HHS, and GAO found DEA factored in that HHS input in all 95 cases. Among the 84 rules in that group that reached final form, DEA's final rule matched HHS's recommendation every single time. On the substance of the matter, in other words, the report is actually a point in favor of the process working as designed.

What GAO flagged instead were process gaps that are bureaucratic rather than substantive. DEA has no written playbook for how it collects data or applies the eight-factor analysis required under the Controlled Substances Act. FDA has no written criteria for how it evaluates abuse potential during its scientific review. And the coordination agreement between FDA and the National Institute on Drug Abuse governing parts of this work is more than 40 years old, predating most of the modern regulatory apparatus both agencies now rely on.

GAO issued three recommendations addressing these gaps, and both DEA and FDA agreed to implement them. That's the entire report. It's a call for better documentation, not a challenge to whether marijuana belongs in Schedule III.

What's Unaffected: The April 2026 Partial Rescheduling

Lost in the noise over the stay is that it only touches the ALJ's recommendation on full Schedule III rulemaking. It does not affect the separate order DEA issued in April 2026, which already reclassified how the agency treats two specific categories of cannabis: FDA-approved marijuana-derived products and marijuana handled under a state-licensed medical marijuana program.

That April order came with a 60-day expedited registration window allowing state-licensed medical cannabis businesses to register with DEA under the new framework. That window closed June 22, 2026. What happened during it is harder to pin down than you'd expect for a federal regulatory action of this size. DEA hasn't published how many businesses applied or were approved, and its public registration database currently returns a message reading No Registrant Population Data Found when queried on the subject — not reassuring for an agency asking the industry to trust a new compliance pathway.

The clearest real number available right now actually comes from the private sector. Trulieve's September 2026 investor presentation disclosed 207 DEA-registered dispensaries across its medical-only state footprint, giving outside observers one of the only concrete data points in an otherwise opaque rollout. Whether that figure is typical of the broader industry or reflects one company moving faster than most isn't something anyone outside DEA can currently verify. Businesses operating under medical licenses in states where this applies should treat the April framework as active and unaffected by the current stay, while recognizing that the registration process itself remains something of a black box. Check your specific state's medical program rules, since eligibility and documentation requirements for federal registration run through those state frameworks first.

A procedural stay built around a GAO report on documentation gaps is nowhere close to derailing rescheduling. DEA and FDA accepted every recommendation in that report without objection, and nothing in it questions the medical or scientific basis for Schedule III. This is bureaucratic caution working through a legal process that, frankly, has plenty of room for additional motions and additional caution before anyone involved runs out of patience.

The bigger threat to this whole effort isn't any single filing — it's accumulated time. Three years since the initial recommendation, a missed 2025 hearing date, a hearing that didn't wrap until mid-2026, and now a stay pushing a nonbinding recommendation further into an election cycle that tends to make federal agencies more cautious, not less. Administrator Cole still hasn't had to act on anything, because nothing has reached his desk yet. That's the quiet frustration embedded in this story: the recommendation everyone's waiting on hasn't even been written.

In the meantime, the part of this that actually affects people operating cannabis businesses today is the April 2026 partial rescheduling, and that part is untouched by any of this. If you're running or working with a state-licensed medical operation, the smart move is watching DEA's registration process directly rather than the ALJ proceeding, since public data on who's registered and how the expedited window played out remains thin to the point of nearly nonexistent. As always, confirm current rules with your state program and legal counsel, since what's federally permitted and what's state-licensed don't always move at the same speed.